Alimera Sciences Цена / балансовая стоимость

Что обозначает Цена / балансовая стоимость в Alimera Sciences?

Цена / балансовая стоимость Alimera Sciences Inc. является 0.36

Какое определение для Цена / балансовая стоимость?



Отношение рыночной цены акции к её балансовой учётной стоимости представляет собой соотношение между стоимостью акций компании и балансовой стоимостью на акцию.

The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).

The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).

P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.

Цена / балансовая стоимость компаний в Health Care сектор на NASDAQ по сравнению с Alimera Sciences

Что делает Alimera Sciences?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Компании с цена / балансовая стоимость похож на Alimera Sciences



  • NWS имеет Цена / балансовая стоимость из 0.36
  • Koenig & Bauer AG имеет Цена / балансовая стоимость из 0.36
  • Best Pacific International имеет Цена / балансовая стоимость из 0.36
  • Bambuser AB (publ) имеет Цена / балансовая стоимость из 0.36
  • Gravity (India) имеет Цена / балансовая стоимость из 0.36
  • Gemdale Properties and Investment имеет Цена / балансовая стоимость из 0.36
  • Alimera Sciences имеет Цена / балансовая стоимость из 0.36
  • Tritax EuroBox plc имеет Цена / балансовая стоимость из 0.36
  • Vasta Platform имеет Цена / балансовая стоимость из 0.36
  • EyePoint Pharmaceuticals Inc имеет Цена / балансовая стоимость из 0.36
  • Valeura имеет Цена / балансовая стоимость из 0.36
  • Devernois S.A имеет Цена / балансовая стоимость из 0.36
  • Inozyme Pharma имеет Цена / балансовая стоимость из 0.37